Health gains |
Estimated potential impact of new TB vaccines on disease burden and transmission (including drug-resistant TB (DR-TB) and co-infection with HIV), as measured by incidence, mortality and morbidity (in the context of alternative strategies) |
Value for money |
Estimated societal cost-effectiveness/cost-utility and return on investment for new TB vaccines from the perspective of both the healthcare payer and society |
Equity and financial risk protection impact |
Estimated impact of a new TB vaccine on equity (in the context of health gains by income distribution and vulnerability) and reduced household financial vulnerability (catastrophic costs and impoverishment) |
Economic impact |
Estimated impact of new TB vaccines on medical and other expenses, as well as on gross domestic product and its rate of growth; estimated impact of new TB vaccines on government expenditure (including expenditure through the HIV response, as applicable) and on sustainability of financing over the long term |
Global health security impact |
新的结核病疫苗对抗微生物管理的估计影响(减少抗生素使用,从而降低抗菌药物的效力降低了继续使用,从而降低了DR-TB疾病的发病率,降低了DR-TB管理的人类和计划成本 |
Market |
Estimated potential demand for new TB vaccines |
Vaccine characteristics and implementation scenario assumptions |
The various parameters above should be evaluated under different vaccine characteristics and implementation scenario assumptions (target population, geographical scope and vaccine characteristics) In addition, the interaction between a new vaccine and alternative strategies (optimal use of current and future alternative interventions) on key outputs should be considered |